| 21.15 |  +0.32 / +1.54% |
Data as of 3:59pm ET | Day’s Change |
| 21.15 |  0.00 / 0.00% |
Volume: 181.00 |
| 1 Reason ABIOMED Looks Attractive Jun 03 / MotleyFool.com | Abiomed Upped to Outperform - Analyst Blog May 29 / Zacks.com |
| Abiomed Gains Reimbursement Approval - Analyst Blog May 30 / Zacks.com | Some Numbers at ABIOMED that Make Your Stock Look Good May 23 / MotleyFool.com |
| Previous close | 20.83 |
| Today’s open | 20.96 |
| Day’s range | 20.76 - 21.17 |
| Volume | 509,210 |
| Average volume (3 months) | 427,350 |
| Market cap | $806.9M |
| Dividend yield | -- |
| Earnings growth (last year) | +825.00% |
| Earnings growth (this year) | -11.79% |
| Earnings growth (next 5 years) | +19.50% |
| Revenue growth (last year) | +25.12% |
| P/E ratio | 57.2 |
| Price/Sales | 4.62 |
| Price/Book | 5.87 |
| Today’s change | Today’s % change | |
|---|---|---|
| LMNXLuminex Corp | +0.02 | +0.10% |
| EXASExact Sciences Corp | +0.21 | +1.77% |
| TRNXTornier NV | -0.10 | -0.64% |
| NUVANuVasive Inc | +0.32 | +1.52% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | $0.06 |
| Annual revenue (last year) | $158.1M |
| Annual profit (last year) | $15.0M |
| Net profit margin | 9.50% |
Sector Health Technology |
Industry Medical Specialties |
Chairman, President & Chief Executive Officer Michael R. Minogue, MBA |
Chief Operating Officer David M. Weber, PhD |
Corporate headquarters Danvers, Massachusetts |
.
